Navigation Links
Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
Date:6/22/2009

statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
2. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Oncothyreon announces closing of $11.1 million registered direct financing
4. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
5. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
6. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
7. Oncothyreon reports first quarter 2009 financial results
8. Oncothyreon regains compliance with NASDAQ listing requirements
9. Oncothyreon to present at Invest Northwest 2009
10. Oncothyreon reports full year and fourth quarter 2008 financial results
11. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., Nov. 20 Cell Therapeut...oday that the Ninth Circuit Court of Appeals rever... should be allowed to pursue all of its claims aga...District Court for trial. CTI filed a complaint a...imbursement consultant for CTI,s product TRISENOX,...
(Date:11/19/2009)...Nov. 19 Danish Prince Joachim inau...anol plant in Kalundborg, Denmark, on Wednesday, N...st and largest 2nd generation ethanol demonstratio...e used in the plant,s innovative process for conve...co, was the first to market with commercial enzyme...
(Date:11/19/2009)...ov. 19 NeoStem, Inc. (NY...the following letter to its shareholders, discussi... of China Biopharmaceuticals Holdings, Inc. (CHBP)...n the People,s Republic of China. The merger gives... Pharmaceutical Co. Ltd., CHBP,s primary operating...
(Date:11/19/2009)...ov. 19 /PRNewswire/ - Aegera Therapeutics Inc. ann...randomized Phase 2B study of AEG35156, a targeted ... multiple oncology indications. ,, The study, e... the X-Linked Inhibitor of Apoptosis (XIAP) Antise...ytarabine and Idarubicin in AML Following Failure ...
Breaking Biology Technology:Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
...dge, Highlight Most Recent ...Educators, an accredited,provider of continuing ed...,of three talented individuals to its staff. Backe...egrees in molecular biology, structural biology,bi...m the top universities,across the nation, each bri...
...asdaq: NEOG ) announced today that its net income.... 31, increased 25% from the previous year,s first...ck split, net income per,share was $0.21 in the fi...ame period in the prior year. First quarter reven...0,to $22,909,000 -- representing a record for reve...
...nc. (Amex: ANX ), a biopharmaceutical research an...roprietary product candidates for the treatment,of...hat data from,preclinical studies of ANX-514 (doce...Association of Cancer Research (AACR), National Ca... Treatment of Cancer (EORTC),International Confere...
Other Biology Technology:ArcMesa Educators Appoints Medical Advisor and Directors to CME Development Team 2ArcMesa Educators Appoints Medical Advisor and Directors to CME Development Team 3Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues 2Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues 3Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues 4Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues 5ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 2ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 3ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 4
(Date:11/20/2009)...all read studies about the health benefits of havi...olecular level, where amino acids known as cystein...than when paired up with other cysteines. , Now,...with colleagues in Belgium, have discovered a new ... The research appears in the Nov. 20 issue of the ...
(Date:11/20/2009)...0, 2009) Scientists from the Marine Biogeochemist...l Research Laboratory (NRL) organized and led a te...rctic expedition to initiate methane hydrate explo...al variation of sediment contribution to Arctic cl...utter Polar Sea as a research platform, three cros...
(Date:11/20/2009)...a single bacterial gene into yeast, researchers fr...ds achieved three improvements in bioethanol produ...nol, less acetate and elimination of the major by-...ished in the scientific journal Applied and Envir...nol is made by the yeast Saccharomyces cerevisiae ...
Breaking Biology News(10 mins):Saving the single cysteine: New antioxidant system found 2International expedition investigates climate change, alternative fuels in Arctic 2Delft breakthrough in bioethanol production from agricultural waste 2ThermoGenesis Provides Update on Fiscal 2009 Results 13429 1ThermoGenesis Provides Update on Fiscal 2009 Results 13429 2ThermoGenesis Provides Update on Fiscal 2009 Results 13429 3ThermoGenesis Provides Update on Fiscal 2009 Results 13429 4ThermoGenesis Provides Update on Fiscal 2009 Results 13429 5OncoGenex Reports Second Quarter 2009 Financial Results 13426 1OncoGenex Reports Second Quarter 2009 Financial Results 13426 2OncoGenex Reports Second Quarter 2009 Financial Results 13426 3OncoGenex Reports Second Quarter 2009 Financial Results 13426 4OncoGenex Reports Second Quarter 2009 Financial Results 13426 5OncoGenex Reports Second Quarter 2009 Financial Results 13426 6OncoGenex Reports Second Quarter 2009 Financial Results 13426 7Combo Treatment May Ease Depression After Stroke 53891 1Combo Treatment May Ease Depression After Stroke 53891 2
... 4, 2008 Researchers at UT Southwestern Medical C...od to screen small synthetic molecules and pull ou...ases less expensively than current methods. , In ...lled peptoids, the new technique quickly singled o...body already on the market for treating cancer. On...
... the Burnham Institute for Medical Research (Burnh...t of a disorder called Sporadic Inclusion Body Myo...s predominantly older men, causing muscles to grad...living with sIBM is unknown, but it is the most co..., and due to its unfamiliarity, it is probably und...
... have noticed that their four-legged friend seem e...ay as five hours, may wonder if animals can tell w... University of Western Ontario in London, Canada m.... , The results of the research, entitled Episodi...Long Ago, appear in the current issue of the journ...
Other Biology News:Synthetic molecules may be less expensive alternative to therapeutic antibodies, researchers find 2Synthetic molecules may be less expensive alternative to therapeutic antibodies, researchers find 3RING finger protein 5 may guide treatment for muscle disease in older adults 2RING finger protein 5 may guide treatment for muscle disease in older adults 3Are animals stuck in time? 2
...ing a protein engineering approach that introduced... wild-type DNase I. These changes markedly increas...is a versatile enzyme that has a 6-fold lower Km f... peak activity in solutions approaching 200 mM mon...
iTaq DNA Polymerase, 250 U from Bio-Rad
Rabbit Anti-hnRNP U Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
...tages in your laboratory or fellow researchers wan...distractions, problems and delays. • Rece...ing us your idea and let us build it up and market...y assurance in design, development, production, in...
Biology Products: